Tonix's Tonmya Disappoints in Second Phase III PTSD Study
But Fibromyalgia Study Continues
Tonix Pharmaceuticals’ sublingual cyclobenzaprine has failed to show better efficacy than placebo in an interim analysis of the Phase III RECOVERY trial in post-traumatic stress disorder patients, although the study will continue to completion in already-enrolled patients. The product is also in development for fibromyalgia.
